Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Lung Cancer

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44351   clinical trials with a EudraCT protocol, of which   7378   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,675 result(s) found for: Lung Cancer. Displaying page 5 of 84.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2010-024061-48 Sponsor Protocol Number: ML25423 Start Date*: 2011-05-25
    Sponsor Name:Roche Bulgaria EOOD
    Full Title: Phase II, open-label study of erlotinib (Tarceva®) treatment in patients with locally advanced, metastatic or recurrent non-small cell lung cancer who present activating mutations in the tyrosine k...
    Medical condition: Locally advanced or metastatic NSCLC of stage IIIb or IV or recurrent NSCLC
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029521 Non-small cell lung cancer stage IIIB PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029515 Non-small cell lung cancer recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: View results
    EudraCT Number: 2008-000617-30 Sponsor Protocol Number: MCC-15005 Start Date*: 2008-09-25
    Sponsor Name:Klinik Loewenstein gGmbH
    Full Title: Randomized Phase III Multicenter Trial of RRM1 & ERCC1 Directed Customized Chemotherapy versus Standard of Care for 1st Line Treatment of Patients with Advanced Non-Small-Cell Lung Cancer
    Medical condition: Patients with untreated advanced stage NSCLC. 2:1 randomization to experimental (A) or standard arm (B). In arm A, treatment of dual-agent chemotherapy will be selected based on RRM1 and ERCC1 ex...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029521 Non-small cell lung cancer stage IIIB LLT
    9.1 10029522 Non-small cell lung cancer stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-009315-22 Sponsor Protocol Number: NVALT10 Start Date*: 2009-02-25
    Sponsor Name:NVALT
    Full Title: A randomized phase II study of erlotinib compared to single agent chemotherapy-erlotinib combination in pretreated patients with advanced NSCLC (NVALT10 study)
    Medical condition: patients who failed previous cytotoxic treatment for non-small-cell lung cancer locally advanced and metastatic disease stage IIIB and IV
    Disease: Version SOC Term Classification Code Term Level
    9.1 10025054 Lung cancer non-small cell stage IIIB LLT
    9.1 10025055 Lung cancer non-small cell stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-001642-28 Sponsor Protocol Number: INCB39110-205 Start Date*: 2015-09-28
    Sponsor Name:Incyte Corporation
    Full Title: A Randomized, Double-Blind Phase 1/2 Study of INCB039110 in Combination With Erlotinib Versus Erlotinib Alone in Subjects With Stage IIIB, Stage IV, or Recurrent Non–Small Cell Lung Cancer Whose Tu...
    Medical condition: Male or female individuals, aged 18 years or older who have Stage IIIB/IV or recurrent NSCLC. Subjects must have tumors that are positive for EGFR-activating mutation, namely, exon 19 deletions, e...
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029521 Non-small cell lung cancer stage IIIB PT
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029515 Non-small cell lung cancer recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-006323-31 Sponsor Protocol Number: D1532C00016 Start Date*: 2009-05-19
    Sponsor Name:AstraZeneca AB
    Full Title: D1532C00016: A Phase II, Double-Blind, Randomised, Placebo-Controlled Study to Assess the Efficacy of AZD6244 (Hyd-Sulfate) in Combination with Docetaxel, Compared with Docetaxel Alone, in 2nd Line...
    Medical condition: 2nd Line Patients with KRAS Mutation Positive Locally Advanced or Metastatic Non Small Cell Lung Cancer (Stage IIIB – IV)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029521 Non-small cell lung cancer stage IIIB LLT
    9.1 10029522 Non-small cell lung cancer stage IV LLT
    9.1 10059515 Non-small cell lung cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) DK (Completed) ES (Completed) BE (Completed) FR (Completed) IT (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2017-004157-16 Sponsor Protocol Number: CABinMET Start Date*: 2018-02-21
    Sponsor Name:FONDAZIONE RICERCA TRASLAZIONALE (FORT)
    Full Title: Phase II single arm study with CABozantinib in Non-Small Cell Lung Cancer patients with MET deregulation
    Medical condition: Stage III B or stage IV non-small cell lung cancer (not a candidate for local therapies with curative intent)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-004167-22 Sponsor Protocol Number: PGT307 Start Date*: 2008-01-23
    Sponsor Name:Cell Therapeutics, Inc.
    Full Title: Paclitaxel poliglumex (CT-2103)/Carboplatin vs Paclitaxel/Carboplatin for the Treatment of Chemotherapy-Naive Advanced Non-Small Cell Lung Cancer (NSCLC) in Women with Estradiol > 30 pg/ml
    Medical condition: Advanced Non-small Cell Lung Cancer (NSCLC) in women.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029515 Non-small cell lung cancer recurrent LLT
    9.1 10029521 Non-small cell lung cancer stage IIIB LLT
    9.1 10029522 Non-small cell lung cancer stage IV LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-000765-33 Sponsor Protocol Number: AGMT_NSCLC 1 Start Date*: 2009-11-19
    Sponsor Name:AGMT gemeinnützige GmbH
    Full Title: Phase II Study to Investigate the Treatment of Patients with NSCLC Stage IIIB and IV without the Option of Surgery with a Combination of Cisplatin, Docetaxel and Bevacizumab
    Medical condition: Inoperable NSCLC, stages IIIB and IV
    Disease: Version SOC Term Classification Code Term Level
    12.0 10029521 Non-small cell lung cancer stage IIIB LLT
    12.0 10029522 Non-small cell lung cancer stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-019384-11 Sponsor Protocol Number: EFC10259 Start Date*: Information not available in EudraCT
    Sponsor Name:sanofi-aventis recherche & développement
    Full Title: A multinational, randomized, double blind, controlled phase II trial of ombrabulin with taxane and platinum combination administered every three weeks, in first line treatment of patients with meta...
    Medical condition: Non-small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    12.1 10061873 Non-small cell lung cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2004-001331-36 Sponsor Protocol Number: EORTC 08021 - ILCP Start Date*: 2005-02-17
    Sponsor Name:IST. DI RICERCHE FARMACOLOG. M. NEGRI
    Full Title: A randomized phase III study of follow-up with or without Gefitinib (IressaTM) following chemotherapy in patients with advanced non-small cell lung cancer.
    Medical condition: Non small cell lung cancer, advanced.
    Disease: Version SOC Term Classification Code Term Level
    6.1 10061873 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-001259-34 Sponsor Protocol Number: FoRT01/2016 Start Date*: 2016-08-31
    Sponsor Name:FONDAZIONE RICERCA TRASLAZIONALE (FORT)
    Full Title: PF-06463922 for crizotinib pretreated ROS1 positive non-small-cell lung cancer: a phase II Trial (PFROST)
    Medical condition: ROS1 positive non-small-cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-003731-20 Sponsor Protocol Number: CEGF816X2201C Start Date*: 2015-05-19
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A phase II, multicenter, open-label study of EGF816 in combination with Nivolumab in adult patients with EGFR mutated non-small cell lung cancer and of INC280 in combination with Nivolumab in adult...
    Medical condition: EGFR mutated non-small cell lung cancer and EGFR wild-type non-small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10025044 Lung cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) ES (Completed) NL (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-001726-13 Sponsor Protocol Number: A4061038 Start Date*: 2008-11-28
    Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York City, NY 10017
    Full Title: PHASE 2 TRIAL OF AG-013736 AS FIRST-LINE TREATMENT FOR PATIENTS WITH SQUAMOUS NON-SMALL CELL LUNG CANCER RECEIVING TREATMENT WITH CISPLATIN AND GEMCITABINE
    Medical condition: Advanced non-small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10059515 Non-small cell lung cancer metastatic PT
    9.1 10029515 Non-small cell lung cancer recurrent LLT
    9.1 10029521 Non-small cell lung cancer stage IIIB LLT
    9.1 10029522 Non-small cell lung cancer stage IV PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: View results
    EudraCT Number: 2005-002438-37 Sponsor Protocol Number: 2005/VCC/0018(WCTU02) Start Date*: 2006-12-07
    Sponsor Name:Velindre NHS Trust
    Full Title: A randomised phase III clinical trial investigating the effect of FRAGMin® Added to standard Therapy In patients with lung Cancer
    Medical condition: Lung cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025044 Lung cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-001736-12 Sponsor Protocol Number: NO21160 Start Date*: 2008-11-12
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A Randomized, placebo controlled study to determine the effect of two dose schedules of R1507 or placebo, both in combination with erlotinib (Tarceva®), on progression-free survival in patients wit...
    Medical condition: To investigate in a randomized fashion if the addition of targeted IGF-1R blockade with R1507 has additional clinical benefit when combined with erlotinib in patients with advanced NSCLC who have f...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029521 Non-small cell lung cancer stage IIIB LLT
    9.1 10029522 Non-small cell lung cancer stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) ES (Completed) AT (Prematurely Ended) DE (Completed) IE (Completed) IT (Completed) FR (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2021-001696-16 Sponsor Protocol Number: SOLUCOM Start Date*: 2021-10-28
    Sponsor Name:Vestre Viken Health Trust
    Full Title: Sotorasib in advanced KRASG12C-mutated non-small cell lung cancer patients with comorbidities
    Medical condition: Advanced KRASG12C-mutated non-small cell lung cancer patients with comorbidities
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025044 Lung cancer LLT
    25.1 100000004850 10069759 KRAS mutation LLT
    22.0 100000004850 10075674 KRAS codon 12 and 13 mutation LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-003201-96 Sponsor Protocol Number: I4X-MC-JFCK Start Date*: 2013-03-13
    Sponsor Name:Eli Lilly and Company
    Full Title: A Single-Arm, Multicenter, Open-Label, Phase 2 Study of Gemcitabine-Cisplatin Chemotherapy Plus Necitumumab (IMC-11F8) in the First-Line Treatment of Patients With Stage IV Squamous Non-Small Ce...
    Medical condition: Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2009-013838-25 Sponsor Protocol Number: IMCLCP11-0806 Start Date*: 2009-10-21
    Sponsor Name:ImClone LLC
    Full Title: A Randomized, Multicenter, Open-Label, Phase 3 Study of Gemcitabine-Cisplatin Chemotherapy Plus Necitumumab (IMC-11F8) Versus Gemcitabine-Cisplatin Chemotherapy Alone in the First-Line Treatment of...
    Medical condition: Advanced squamous non small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) AT (Completed) DE (Completed) HU (Completed) PT (Completed) ES (Ongoing) GR (Ongoing) SK (Completed) IT (Completed) GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2008-006384-37 Sponsor Protocol Number: NP22383 Start Date*: 2009-10-06
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A phase II study of orally administered RO4929097, a gamma-secretase inhibitor, as a single agent in patients with recurrent or refractory Non-Small Cell Lung Cancer (NSCLC).
    Medical condition: Patients with recurrent or refractory stage IIIB/IV NSCLC.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029515 Non-small cell lung cancer recurrent LLT
    9.1 10029521 Non-small cell lung cancer stage IIIB LLT
    9.1 10029522 Non-small cell lung cancer stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-020229-42 Sponsor Protocol Number: ML21869 Start Date*: 2010-07-18
    Sponsor Name:ROCHE
    Full Title: A randomized phase II trial of erlotinib (TARCEVA) or intermittent dosing of erlotinib and docetaxel in male former smokers with locally advanced or metastatic squamous nonsmall cell lung cancer...
    Medical condition: Non-small cell lung cancer (NSCLC), locally advanced (stage IIIB), metastatic (stage IV) or recurrent.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029521 PT
    9.1 10029522 PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Jul 25 05:04:21 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA